ELANE — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL121431	1.00	20/20
SCHEMBL123590	1.00	20/20
SCHEMBL122465	0.87	20/20
SCHEMBL123537	0.87	20/20
SCHEMBL121570	0.87	20/20
SCHEMBL122824	0.87	20/20
SCHEMBL124342	0.87	20/20
SCHEMBL122597	0.86	20/20
SCHEMBL125296	0.84	20/20
SCHEMBL122610	0.84	20/20
SCHEMBL124884	0.84	20/20
SCHEMBL123593	0.83	20/20
SCHEMBL125403	0.83	20/20
SCHEMBL124750	0.83	20/20
SCHEMBL123135	0.82	20/20
SCHEMBL121808	0.81	20/20
SCHEMBL122973	0.81	20/20
SCHEMBL124062	0.81	20/20
SCHEMBL124648	0.81	20/20
SCHEMBL124948	0.81	20/20

Clinical trials — most relevant to ELANE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function	PHASE4	COMPLETED
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19	PHASE3	COMPLETED
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema	PHASE2/PHASE3	COMPLETED
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency	PHASE2	COMPLETED
Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation	PHASE2	COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients	PHASE2	COMPLETED
28 Day Repeat Dose in Cystic Fibrosis Patients	PHASE2	COMPLETED
Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS	PHASE1	UNKNOWN
Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs	EARLY_PHASE1	COMPLETED
The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping	nan	ACTIVE_NOT_RECRUITING
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)	nan	RECRUITING
Analytical Performance of pH, HNE and MPO Levels in Detecting Wound Infection Proof of Concept Biomarker Study	nan	WITHDRAWN
EDN and Eosinophilic Esophagitis	nan	RECRUITING
Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant	nan	COMPLETED
Genomic Research in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
Serum Esnophilic Cationic Protein Level as Diagnostic Marker in Cow Milk Protein Allergy Infants	nan	UNKNOWN
Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery	nan	COMPLETED
Eosinophilic Cationic Protein as a Biomarker in Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease	nan	UNKNOWN
Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)	nan	UNKNOWN
Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis	nan	COMPLETED
Post Acute Pancreatitis Pancreatic Exocrine Insufficiency	nan	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa.	nan	NOT_YET_RECRUITING
Effect of Mepolizumab on Severe Eosinophilic Asthma	nan	UNKNOWN
Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy	nan	COMPLETED
Mechanisms of Acute Kidney Injury in Severe Infections	nan	RECRUITING
High Frequency Chest Wall Oscillation in Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Esophageal String Test in Eosinophilic Esophagitis	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ELANE binder may also engage these)

Protein	Name	Similarity
Q3UP87	—	0.996	Q3UP87 →
P20160	—	0.976	P20160 →
P80015	—	0.968	P80015 →
Q9GL10	—	0.963	Q9GL10 →
P32038	—	0.962	P32038 →
P03953	—	0.958	P03953 →
B8V7S0	—	0.957	B8V7S0 →
Q17004	—	0.956	Q17004 →
A7LAC6	—	0.956	A7LAC6 →
Q8AY81	—	0.955	Q8AY81 →
E5L0E6	—	0.955	E5L0E6 →
B5U6Y3	—	0.955	B5U6Y3 →
Q8UUJ1	—	0.955	Q8UUJ1 →
Q8VHJ4	—	0.954	Q8VHJ4 →
P0DJF6	—	0.954	P0DJF6 →
Q9PTU8	—	0.954	Q9PTU8 →
Q9PT51	—	0.954	Q9PT51 →
Q9I8X2	—	0.954	Q9I8X2 →
Q9PTL3	—	0.953	Q9PTL3 →
O73800	—	0.953	O73800 →
P85109	—	0.953	P85109 →
J3RYA3	—	0.953	J3RYA3 →
Q00356	—	0.953	Q00356 →
Q86WS5	—	0.952	Q86WS5 →
D8MIA2	—	0.952	D8MIA2 →
Q05511	—	0.952	Q05511 →
E0Y421	—	0.952	E0Y421 →
P08884	—	0.951	P08884 →
Q5R5E8	—	0.951	Q5R5E8 →
Q8VHK8	—	0.951	Q8VHK8 →